ozanimod vs Ponesimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb and partners
NCT02435992 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.
Next expected readout: July 2032 · NCT05076175 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at 10 Weeks; Percentage of Participants in Clinical Remission at 52 Weeks: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) (met)
Result source: NCT02435992
Ponesimod
Marketed by Vanda Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2029 · NCT07686081 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ozanimod | Ponesimod |
|---|---|---|
| Clinical remission (induction) | 18.4% vs 6%+12.4 vs placeboNCT024359923 other results
| —Trial running · NCT07686081 |
| Clinical remission (maintenance) | 37% vs 18.5%+18.5 vs placeboNCT024359922 other results
| —Trial running · NCT07686081 |
| Clinical response (induction) | 47.8% vs 25.9%+21.9 vs placeboNCT024359923 other results
| —Trial running · NCT07686081 |
| Endoscopic improvement (induction) | 27.3% vs 11.6%+15.7 vs placeboNCT024359923 other results
| —Trial running · NCT07686081 |
| Corticosteroid-free remission (maintenance) | 31.7% vs 16.7%+15 vs placeboNCT02435992 | —Trial running · NCT07686081 |
Clinical remission (induction)
- ozanimod
- 18.4% vs 6%+12.4 vs placeboNCT02435992
3 other results
- 21% vs 6% NCT02435992
- 16.4% vs 6.2% NCT01647516
- 13.8% vs 6.2% NCT01647516
- Ponesimod
- —Trial running · NCT07686081
Clinical remission (maintenance)
- ozanimod
- 37% vs 18.5%+18.5 vs placeboNCT02435992
2 other results
- 20.9% vs 6.2% NCT01647516
- 26.2% vs 6.2% NCT01647516
- Ponesimod
- —Trial running · NCT07686081
Clinical response (induction)
- ozanimod
- 47.8% vs 25.9%+21.9 vs placeboNCT02435992
3 other results
- 52.6% vs 25.9% NCT02435992
- 56.7% vs 36.9% NCT01647516
- 53.8% vs 36.9% NCT01647516
- Ponesimod
- —Trial running · NCT07686081
Endoscopic improvement (induction)
- ozanimod
- 27.3% vs 11.6%+15.7 vs placeboNCT02435992
3 other results
- 27.2% vs 11.6% NCT02435992
- 34.3% vs 12.3% NCT01647516
- 27.7% vs 12.3% NCT01647516
- Ponesimod
- —Trial running · NCT07686081
Corticosteroid-free remission (maintenance)
- ozanimod
- 31.7% vs 16.7%+15 vs placeboNCT02435992
- Ponesimod
- —Trial running · NCT07686081
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ponesimod: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ozanimod: 4 of 4 rows · Ponesimod: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ozanimod |
|---|---|
| Dropout rate | —1mga NCT02435992 · Phase 3 · monotherapy show 15 more results—1mg NCT02435992 · Phase 3 · monotherapy —1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy 11.7%RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 46.3%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 69.5%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 6%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 4.5%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —1mga NCT02435992 · Phase 3 · monotherapy show 15 more results—1mg NCT02435992 · Phase 3 · monotherapy —1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy 3.3%RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 7.4%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 6.1%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 3%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4%1mga NCT02435992 · Phase 3 · monotherapy show 15 more results6.3%1mg NCT02435992 · Phase 3 · monotherapy 5.2%1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy —RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 14.8%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 17.2%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy 3%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 2.4%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 18.6%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 1.5%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 0%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 25%0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 9.1%Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 11 more resultscovid-19 25.9% (placebo 16.8%) lymphopenia 16.7% (placebo 17.3%) leukopenia 7.4% (placebo 4.1%) NCT02531126 · Phase 3 · monotherapy lymphopenia 16.3% (placebo 17.3%) covid-19 11.3% (placebo 16.8%) lymphocyte count decreased 10.8% (placebo 12.8%) NCT02531126 · Phase 3 · monotherapy 1 mg alanine aminotransferase increased 3% (placebo 0%) headache 3% (placebo 4.6%) anaemia 1.5% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 1 mg alanine aminotransferase increased 2.4% (placebo 0%) colitis ulcerative 2.4% (placebo 1.5%) anaemia 0% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 1 mg hypertension 11.9% (placebo 0%) gamma-glutamyltransferase increased 8.5% (placebo 0%) upper respiratory tract infection 8.5% (placebo 3.1%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg anaemia 6.2% (placebo 6.2%) colitis ulcerative 3.1% (placebo 1.5%) back pain 1.5% (placebo 1.5%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg alanine aminotransferase increased 2.8% (placebo 0%) nasopharyngitis 2.8% (placebo 0%) anaemia 0% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg/1 mg anaemia 5.4% (placebo 6.2%) gamma-glutamyltransferase increased 5.4% (placebo 0%) lymphocyte count decreased 5.4% (placebo 0%) NCT01647516 · Phase 2 · registry result, not featured evidence anaemia 7.3% (placebo 6.2%) colitis ulcerative 7.3% (placebo 1.5%) bronchitis 5.5% (placebo 0%) NCT01647516 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ozanimod
show 6 more results
show 6 more results
show 6 more results
show 2 more results
show 4 more results
show 4 more results
show 9 more results
show 4 more results
show 9 more results
show 9 more results
+ 6 further endpoints in the CSV export.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb and partners
NCT01628393 · Phase 2/3 · completed
The trial was randomized, placebo-controlled and fully blinded in 258 participants, and both ozanimod doses significantly reduced new brain lesions on MRI versus placebo. Because the primary measure was an imaging biomarker rather than a clinical outcome such as relapse rate or disability, this trial supports but does not on its own confirm a clinical benefit.
Next expected readout: August 2028 · NCT06529406 (registry estimate)
Reported efficacy
Adjusted Annualized Relapse Rate (ARR) at the End of Month 24: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose (met)
Result source: NCT02047734
Ponesimod
Marketed by Vanda Pharmaceuticals and partners
NCT02425644 · Phase 3 · completed
This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.
Reported efficacy
Annualized Confirmed Relapse Rate (From randomization to end of study (Week 108)): Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. (met)
Result source: NCT02425644
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ozanimod | Ponesimod |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.3vs Interferon Beta-1aNCT020477345 other results
| 0.2 vs 0.3vs TeriflunomideNCT02425644 |
| Free of 3-month confirmed disability progression (%) | —Trial running · NCT06408259 | —Not reported |
| New or enlarging T2 lesions | 0.8 vs 9−8.2 vs placeboNCT016283931 other result
| —Not reported |
Annualised relapse rate
- ozanimod
- 0.2 vs 0.3vs Interferon Beta-1aNCT02047734
5 other results
- 0.2 vs 0.3 NCT02294058
- 0.2 vs 0.3 NCT02047734
- 0.2 vs 0.3 NCT02294058
- 0.2 vs 0.5 NCT01628393
- 0.3 vs 0.5 NCT01628393
- Ponesimod
- 0.2 vs 0.3vs TeriflunomideNCT02425644
Free of 3-month confirmed disability progression (%)
- ozanimod
- —Trial running · NCT06408259
- Ponesimod
- —Not reported
New or enlarging T2 lesions
- ozanimod
- 0.8 vs 9−8.2 vs placeboNCT01628393
1 other result
- 1.4 vs 9 NCT01628393
- Ponesimod
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. ozanimod: 6 of 6 rows · Ponesimod: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ozanimod Rows use multiple source trials | Ponesimod Rows use multiple source trials |
|---|---|---|
| Brain Volume percent change · % of baseline Extension (open-label) | -1.922% (n=623) vs -1.889% (n=596) IFN-B-1a @ 312wk1.0 mga,b,c,d NCT02576717 · Phase 3 · registry result, not featured evidence show 1 more dose-1.696% (n=611) vs -1.889% (n=596) IFN-B-1a @ 312wk0.5 mg NCT02576717 · Phase 3 · registry result, not featured evidence | -2.52% (n=196) vs -2.72% (n=193) Teriflunomide then Ponesimod20 mgb,c,d NCT03232073 · Phase 3 · registry result, not featured evidence |
| Time to First Relapse time to event · months Extension (open-label) | NA vs NA IFN-B-1a months1.0 mga,b,c,d NCT02576717 · Phase 3 · registry result, not featured evidence show 1 more doseNA vs NA IFN-B-1a months0.5 mg NCT02576717 · Phase 3 · registry result, not featured evidence | 92.93 vs NA Teriflunomide then Ponesimod months*20 mgb,c,d NCT03232073 · Phase 3 · registry result, not featured evidence · converted to months from 402.71 weeks as posted |
| Dropout rate | —1.0 mge NCT01628393 · Phase 2/3 show 11 more results1.2%1 mg NCT01628393 · Phase 2/3 —1.0 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 2.3%0.5 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 10.6%1 mg NCT02047734 · Phase 3 15.6%0.5 mg NCT02047734 · Phase 3 6.5%1 mg NCT02294058 · Phase 3 5.8%0.5 mg NCT02294058 · Phase 3 20.9%1.0 mg NCT02576717 · Phase 3 · registry result, not featured evidence 21%0.5 mg NCT02576717 · Phase 3 · registry result, not featured evidence | 13.6%20 mge NCT02425644 · Phase 3 show 4 more results19.8%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 33.9%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 35%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 38.3%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —1.0 mge NCT01628393 · Phase 2/3 show 11 more results—1 mg NCT01628393 · Phase 2/3 —1.0 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 3%1 mg NCT02047734 · Phase 3 2.9%0.5 mg NCT02047734 · Phase 3 2.9%1 mg NCT02294058 · Phase 3 1.6%0.5 mg NCT02294058 · Phase 3 3%1.0 mg NCT02576717 · Phase 3 · registry result, not featured evidence 3.7%0.5 mg NCT02576717 · Phase 3 · registry result, not featured evidence | 2.3%20 mge NCT02425644 · Phase 3 show 4 more results1.6%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 0.8%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 3.4%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 1.7%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 7.3%1.0 mge NCT01628393 · Phase 2/3 show 11 more results—1 mg NCT01628393 · Phase 2/3 0%1.0 mg NCT01628393 · Phase 2/3 7.9%0.5 mg NCT01628393 · Phase 2/3 —0.5 mg NCT01628393 · Phase 2/3 3.4%0.5 mg NCT01628393 · Phase 2/3 6.5%1 mg NCT02047734 · Phase 3 7.1%0.5 mg NCT02047734 · Phase 3 2.9%1 mg NCT02294058 · Phase 3 3.5%0.5 mg NCT02294058 · Phase 3 15.5%1.0 mg NCT02576717 · Phase 3 · registry result, not featured evidence 15.7%0.5 mg NCT02576717 · Phase 3 · registry result, not featured evidence | 8.7%20 mge NCT02425644 · Phase 3 show 4 more results12.8%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 24.1%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 16.6%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 23%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 1.0 mge nasopharyngitis 13.8% (placebo 13.6%) alanine aminotransferase increased 9.8% (placebo 0%) upper respiratory tract infection 8.9% (placebo 3.4%) NCT01628393 · Phase 2/3 show 9 more results1.0 mg gamma-glutamyltransferase increased 6% (placebo 0%) nasopharyngitis 6% (placebo 13.6%) alanine aminotransferase increased 4.8% (placebo 0%) NCT01628393 · Phase 2/3 0.5 mg upper respiratory tract infection 15.9% (placebo 3.4%) nasopharyngitis 13.5% (placebo 13.6%) gamma-glutamyltransferase increased 8.7% (placebo 0%) NCT01628393 · Phase 2/3 0.5 mg nasopharyngitis 12.6% (placebo 13.6%) urinary tract infection 6.9% (placebo 2.3%) back pain 5.7% (placebo 10.2%) NCT01628393 · Phase 2/3 0.5 mg nasopharyngitis 13.4% headache 12.5% upper respiratory tract infection 8.2% NCT02047734 · Phase 3 1.0 mg nasopharyngitis 20.9% (placebo 13.5%) headache 17% (placebo 5.4%) covid-19 16.1% (placebo 21.6%) NCT02576717 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 21% (placebo 13.5%) headache 16.9% (placebo 5.4%) covid-19 15.5% (placebo 21.6%) NCT02576717 · Phase 3 · registry result, not featured evidence | 20 mge alanine aminotransferase increased 19.5% nasopharyngitis 19.3% headache 11.3% NCT02425644 · Phase 3 show 4 more results20 mg covid-19 26.2% nasopharyngitis 18.7% alanine aminotransferase increased 16.6% NCT03232073 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 31.7% headache 21.4% upper respiratory tract infection 19.3% NCT01093326 · Phase 2 · registry result, not featured evidence 40 mg nasopharyngitis 29.8% headache 27.2% upper respiratory tract infection 25.8% NCT01093326 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 33.1% headache 27.3% upper respiratory tract infection 19.4% NCT01093326 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ozanimod
show 7 more results
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
+ 20 further endpoints in the CSV export.
Ponesimod
show 1 more result
show 1 more result
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ozanimod's landscape · Ponesimod's landscape